Lung Clinic Grosshansdorf-Department of Thoracic Oncology 22927 Grosshansdorf (Schleswig-Holstein) GermanyRekrutierend» Google-MapsKöln-Merheim 51109 Köln (Nordrhein-Westfalen) GermanyRekrutierend» Google-MapsPius-Hospital Oldenburg Medizinischer Campus Universität Oldenburg Oldenburg (Niedersachsen) GermanyRekrutierend» Google-MapsHighlands Oncology Group 72762 Springdale United StatesZurückgezogen» Google-MapsLeonard Cancer Institute 92961 Mission Viejo United StatesAktiv, nicht rekrutierend» Google-MapsUC Davis Comprehensive Cancer Center 95817 Sacramento United StatesRekrutierend» Google-Maps Ansprechpartner: Snoti A. Kumeh Phone: 916-734-3608 E-Mail: sakumeh@ucdavis.ed» Ansprechpartner anzeigenProvidence Medical Foundation Santa Rosa 95403 Santa Rosa United StatesRekrutierend» Google-Maps Ansprechpartner: Melissa Phillips Phone: 707-521-3833 E-Mail: melissa.phillips2@stjoe.org
Tracy Foster Phone: 707 521 3833 E-Mail: tracy.foster@stjoe.org» Ansprechpartner anzeigenSarah Cannon- FCS South 33916 Fort Myers United StatesRekrutierend» Google-Maps Ansprechpartner: Lynn Bentz E-Mail: lbentz@flcancer.com» Ansprechpartner anzeigenSarah Cannon- FCS North 33705 Saint Petersburg United StatesRekrutierend» Google-Maps Ansprechpartner: Dinah Welsh-Barnes Phone: 727-216-1143 Phone (ext.): 13097 E-Mail: diBarnes@flcancer.com» Ansprechpartner anzeigenSarah Cannon- FCS Panhandle 32308 Tallahassee United StatesRekrutierend» Google-Maps Ansprechpartner: Patty Wright Phone: 850-877-8166 E-Mail: pwright@flcancer.com» Ansprechpartner anzeigenSarah Cannon- FCS East 33401 West Palm Beach United StatesRekrutierend» Google-Maps Ansprechpartner: Jennifer Bar-Nur, RN Phone: 561-472-1696 E-Mail: jbar-nur@flcancer.com» Ansprechpartner anzeigenBaptist Health Lexington 40503 Lexington United StatesRekrutierend» Google-Maps Ansprechpartner: Karli Heasley, BPH Phone: 859-260-6464 E-Mail: karli.heasley@BHSI.COM
Mina Rogers, MPH Phone: 859.639.3865 E-Mail: Mina.Rodgers@bhsi.com» Ansprechpartner anzeigenBaptist Health Louisville 40207 Louisville United StatesRekrutierend» Google-Maps Ansprechpartner: Kelly Strange Phone: 502-928-6103 E-Mail: kelly.strange@bhsi.com
Renee Dickerson, RN, BSN, CCRC Phone: 502-928-6102 E-Mail: renee.dickerson1@bhsi.com» Ansprechpartner anzeigenBaptist Health Paducah 42003 Paducah United StatesZurückgezogen» Google-MapsMercy Hospital Joplin Missouri 65804 Joplin United StatesAktiv, nicht rekrutierend» Google-MapsMercy Hospital South 63128 Saint Louis United StatesZurückgezogen» Google-MapsMercy Oncology Research St. Louis 63141 Saint Louis United StatesRekrutierend» Google-Maps Ansprechpartner: Erin Cattoor E-Mail: Erin.Cattoor@mercy.net
Jessica Black E-Mail: Jessica.Black@mercy.net» Ansprechpartner anzeigenHackensack Meridian Health 07753 Neptune United StatesRekrutierend» Google-Maps Ansprechpartner: Denise M. Theiler, MSN,RN,CHPN,OCN Phone: 732-897-2871» Ansprechpartner anzeigenSarah Cannon- Messino Cancer Center 28803 Asheville United StatesRekrutierend» Google-Maps Ansprechpartner: Josh Duckett Phone: 828-212-7021 Phone (ext.): 65319 E-Mail: josh.duckett@aoncology.com
Karen Smith Phone: 828-212-7021 Phone (ext.): 65403 E-Mail: Karen.Smith@aoncology.com» Ansprechpartner anzeigenMercy Oncology Research Oklahoma City 73120 Oklahoma City United StatesAktiv, nicht rekrutierend» Google-MapsAllegheny Health Network Research Institute 15212 Pittsburgh United StatesRekrutierend» Google-Maps Ansprechpartner: Meredith Schwarz, RN Phone: 412-592-8162 E-Mail: meredith.schwarz@ahn.org» Ansprechpartner anzeigenSt. Francis Cancer Center 29607 Greenville United StatesRekrutierend» Google-Maps Ansprechpartner: Taylor Crowe Phone: 864-603-6220 E-Mail: ashley_crowe2@bshsi.org» Ansprechpartner anzeigenSarah Cannon Tennessee Oncology 37203 Nashville United StatesRekrutierend» Google-Maps Ansprechpartner: Brittany Callaway Phone: 615-329-7283 E-Mail: brittany.callaway@sarahcannon.com» Ansprechpartner anzeigenSwedish Cancer Institute 98104 Seattle United StatesRekrutierend» Google-Maps Ansprechpartner: Andrew Smith Phone: 206-265-2937 E-Mail: andrew.smith@swedish.org
Renae Koepke Phone: 206-386-2441 E-Mail: renae.koepke@swedish.org» Ansprechpartner anzeigenToulon HIA Sainte Anne- 83800 Toulon FranceRekrutierend» Google-MapsPolyclinique Bordeaux Nord Bordeaux FranceRekrutierend» Google-MapsHôpital Charles Nicolle 76031 Rouen FranceRekrutierend» Google-MapsCHU d'Angers Service Pneumologie 49033 Angers FranceRekrutierend» Google-MapsCentre Hospitalier de la Côte Basque 33077 Bayonne FranceRekrutierend» Google-MapsCHRU Besançon- Hôpital J. MINJOZ 25000 Besancon FranceRekrutierend» Google-MapsHôpital APHP Ambroise Paré 92104 Boulogne FranceRekrutierend» Google-MapsHia Percy 92141 Clamart FranceNoch nicht rekrutierend» Google-MapsCentre Hospitalier Intercommunal de Créteil 94000 Créteil FranceRekrutierend» Google-MapsCentre Hospitalier Départemental Vendée 85925 La Roche-sur-yon FranceRekrutierend» Google-MapsHôpital Privé Jean Mermoz 69008 Lyon FranceRekrutierend» Google-MapsHôpital Europeen 13291 Marseille FranceRekrutierend» Google-MapsHôpital Nord 13915 Marseille FranceRekrutierend» Google-MapsGroupe Hospitalier Région de Mulhouse Sud -Alsace 680100 Mulhouse FranceRekrutierend» Google-MapsCentre Hospitalier Universitaire de Nîmes 30029 Nîmes FranceRekrutierend» Google-MapsHôpital Cochin 75014 Paris FranceRekrutierend» Google-MapsHôpital Tenon 75020 Paris FranceRekrutierend» Google-MapsHôpital Paris Saint Joseph 75674 Paris FranceRekrutierend» Google-MapsHôpital Bichat 75877 Paris FranceRekrutierend» Google-MapsHôpital Haut-Lévèque (Bordeaux - CHU) 33604 Pessac FranceRekrutierend» Google-MapsChu de Poitiers 86021 Poitiers FranceRekrutierend» Google-MapsHôpital Larrey 31059 Toulouse FranceRekrutierend» Google-MapsCHRU de Tours 37044 Tours FranceRekrutierend» Google-MapsGustave Roussy 94805 Villejuif FranceNoch nicht rekrutierend» Google-Maps
1. Disease-Free Survival (Time Frame - 5 years): To compare Disease Free Survival in patients with resected, stage I or IIA non-squamous NSCLC found to be at intermediate or high risk by the 14-Gene Prognostic Assay randomized to either observation or adjuvant therapy with 4 cycles of a platinum-based doublet.
Secondary outcome:
1. Overall Survival (Time Frame - 5 years): To compare Overall Survival in patients randomized to each study arm. To further document the previously verified separation of the survival curves among high and low risk patients identified by the 14-Gene Prognostic Assay in this prospective cohort of stage I or IIA non-squamous NSCLC.
Active Comparator: Observation Post-operative observation of Stage I or Stage IIA non squamous non-small cell lunger cancer with Radiographic Surveillance is a current standard of care. Patients identified as low risk will be observation. Those patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Adjuvant Chemotherapy Arm.
Active Comparator: Adjuvant Chemotherapy Adjuvant Chemotherapy is a current standard of care for intermediate or high-risk Stage I or Stage IIA non-squamous non-small cell lung cancer. Patients identified as intermediate or high-risk by the 14-Gene Prognostic Assay will be randomized either to this arm or the Observation Arm.
Adjuvant Chemotherapy: Patients who have undergone complete resection of NSCLC that has been documented histologically to be non-squamous and that is pathological Stage I or IIA, will undergo testing with the 14-Gene Prognostic Assay. Patients determined to be intermediate or high risk and who meet all eligibility criteria will be randomized either to observation or to four cycles of adjuvant therapy with a standard NSCLC platinum-based doublet.
Radiographic surveillance: Serial radiographic surveillance is a current standard of care for Stage I or Stage IIA lung cancer. All intermediate or high risk patients randomized to observation or chemotherapy will have routine CT Scans at 6 month intervals until 5 years after enrollment and at yearly intervals thereafter until the end of the study period.
14-Gene Prognostic Assay: This CLIA-approved assay is a standard tool that is now available to all clinicians to improve the prognostic evaluation of patients after resection of Stage I or Stage IIA non-squamous NSCLC. It will be performed on tumor specimens for patients who are potentially eligible for this study. Patients identified through the assay as intermediate or high-risk will be randomized to either adjuvant chemotherapy or observation.
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!